The efficacy of H. pylori eradication or screen-and-eradication strategy in the risk reduction of gastric cancer: ongoing trials
Country registration number | Subjects/design | Experiment group | Control group | Primary outcome | Age (years) | Sample size/status | Start year/expected completion year |
Effectiveness of H. pylori eradication | |||||||
China/ChiCTR-TRC-10000979 | Healthy subjects/double blind | Bismuth quadruple therapy | Bismuth + omeprazole + placebo | Gastric cancer incidence | 25–54 | 94 101/recruitment completed | 2011–2013/NA |
Korea/NCT02112214 | Healthy H. pylori infected subjects/double blind | Bismuth quadruple therapy | Placebo | Gastric cancer incidence | 40–60 | 5224/recruitment completed | 2014/2029 |
UK/NCT01506986 | H. pylori-infected aspirin user/double blind | Triple therapy | Placebo | Peptic ulcer bleeding | ≥60 | 3038/recruitment completed | 2012/2021 |
Effectiveness of screening and eradication of H. pylori | |||||||
UK/ISRCTN71557037 | Healthy subjects/open label | H. pylori screening | No screening | Gastric cancer incidence and mortality | M: 35–69; F:45–69 | 56 000/recruitment completed | 1997/2021 |
Taiwan/NCT01741363 | Healthy subjects/open label | H. pylori screening and FIT | FIT alone | Gastric cancer incidence | 50–69 | 60 000/recruitment completed | 2014/2017 |
Latvia/NCT02047994 | Healthy subjects/open label | H. pylori screening and FIT | FIT alone | Gastric cancer mortality | 40–64 | 30 000/recruiting | 2013/2033 |
FIT, faecal immunochemical test; NA, not available.